Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
P 2 (2)

Trial Status

Recruiting2
Not Yet Recruiting2
Unknown1

Clinical Trials (5)

Showing 5 of 5 trials
NCT06698146Recruiting

Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection

NCT07321847Phase 2Not Yet Recruiting

Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases

NCT06801665Phase 2RecruitingPrimary

FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis

NCT06069960Not ApplicableNot Yet RecruitingPrimary

SALT for Unresectable Colorectal Liver Metastases

NCT02758977Not ApplicableUnknownPrimary

Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM)

Showing all 5 trials

Research Network

Activity Timeline